Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get two FREE E-Books

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Depression: 21st Century Solutions + The Dark Side of Wheat


Why You Don't See Ads on GreenMedInfo

Did you know that GreenMedInfo.com is 100% member supported? It is through your membership that we are able to add research content daily, provide thoughtful articles on groundbreaking health & wellness topics, and continue to educate and empower people on the science supporting natural healing.

Our website has always offered open access to our carefully curated research (and always will) but we recently made the decision to become completely advertisement free.

In order for us to continue, we need your support more than ever. Our memberships start at only $8.00 per month and provide you with enhanced content & features.

We appreciate you supporting our mission and sharing our passion!

For more information on becoming a member of GreenMedInfo.com, click here.

Abstract Title:

MELATONIN AND MELATONIN AGONISTS AS ADJUNCTIVE TREATMENTS IN BIPOLAR DISORDERS.

Abstract Source:

Curr Pharm Des. 2015 Jun 18. Epub 2015 Jun 18. PMID: 26088111

Abstract Author(s):

Pierre Alexis Geoffroy, Bruno Etain, Jean-Arthur Micoulaud Franchi, Frank Bellivier, Philipp Ritter

Article Affiliation:

Pierre Alexis Geoffroy

Abstract:

Bipolar disorders (BD) present with abnormalities of circadian rhythmicity and sleep homeostasis, even during phases of remission. These abnormalities are linked to the underlying neurobiology of and genetic susceptibility to BD. Melatonin is a pineal gland secreted neurohormone that induces circadian-related and sleep-related responses. Exogenous melatonin has demonstrated efficacy in treating primary insomnia, delayed sleep phase disorder, improving sleep parameters and overall sleep quality, and some psychiatric disorders like autistic spectrum disorders. In order to evaluate the efficacy of melatonin among patients with BD, this comprehensive review emphasizes the abnormal melatonin function in BD, the rationale of melatonin action in BD, the available data about the exogenous administration of melatonin, and melatonin agonists (ramelteon and tasimelteon), and recommendations of use in patients with BD. There is a scientific rationale to propose melatonin-agonists as an adjunctive treatment of mood stabilizers in treating sleep disorders in BD and thus to possibly prevent relapses when administered during remission phases. We emphasized the need to treat insomnia, sleep delayed latencies and sleep abnormalities in BD are prodromal markers of an emerging mood episode and possible targets to prevent future relapses. An additional interesting adjunctive therapeutic effect might be on preventing metabolic syndrome, particularly in patients treated with antipsychotics. Finally, melatonin is well tolerated and has little dependence potential in contrast to most available sleep medications. Future studies are expected to be able to produce stronger evidence-based therapeutic guidelines to confirm and delineate the routine use of melatonin-agonists in the treatment of BD.

Study Type : Review

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get two FREE E-Books

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Depression: 21st Century Solutions + The Dark Side of Wheat

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2018 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.